Stephen L Hart
Overview
Explore the profile of Stephen L Hart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
988
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maeshima R, Tagalakis A, Gyftaki-Venieri D, Jones S, Rye P, Tondervik A, et al.
Adv Healthc Mater
. 2024 Nov;
14(1):e2400510.
PMID: 39533498
Airway mucus is a major barrier to the delivery of lipid-based nanoparticles in chronic airway diseases such as cystic fibrosis (CF). Receptor-Targeted Nanocomplexes (RTN), comprise mixtures of cationic lipids and...
2.
Vila-Gonzalez M, Pinte L, Fradique R, Causa E, Kool H, Rodrat M, et al.
Respir Res
. 2024 Apr;
25(1):180.
PMID: 38664797
Background: Pulmonary ionocytes have been identified in the airway epithelium as a small population of ion transporting cells expressing high levels of CFTR (cystic fibrosis transmembrane conductance regulator), the gene...
3.
Guri-Lamce I, Alrokh Y, Graham C, Maeshima R, Rognoni E, Caley M, et al.
J Invest Dermatol
. 2024 Apr;
144(10):2314-2317.e3.
PMID: 38583743
No abstract available.
4.
Guri-Lamce I, Alrokh Y, Kim Y, Maeshima R, Graham C, Hart S, et al.
Br J Dermatol
. 2023 Dec;
190(5):617-627.
PMID: 38149939
Patients living with inherited skin diseases have benefited from recent advances in DNA sequencing technologies that provide new or improved diagnostics. However, developing and delivering new treatments for the 'genodermatoses'...
5.
Walker A, Graham C, Greenwood M, Woodall M, Maeshima R, OHara-Wright M, et al.
Mol Ther Methods Clin Dev
. 2023 Nov;
31:101140.
PMID: 38027060
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the gene. The 10th most common mutation, c.3178-2477C>T (3849+10kb C>T), involves a cryptic, intronic splice site. This mutation...
6.
Maeshima R, Jacobs A, Dalbay M, Hart S
Methods Mol Biol
. 2023 Oct;
2725:225-237.
PMID: 37856028
Air-liquid interface (ALI)-cultured cells are widely used as in vitro models of the human respiratory airway in studies of pulmonary physiology, disease, and therapies. However, the primary basal cells required...
7.
Grant-Serroukh D, Hunter M, Maeshima R, Tagalakis A, Aldossary A, Allahham N, et al.
J Control Release
. 2022 Jun;
348:786-797.
PMID: 35718210
Despite recent advances in the field of mRNA therapy, the lack of safe and efficacious delivery vehicles with pharmaceutically developable properties remains a major limitation. Here, we describe the systematic...
8.
Tagalakis A, Jayarajan V, Maeshima R, Ho K, Syed F, Wu L, et al.
Adv Funct Mater
. 2022 Jun;
31(37):2104843.
PMID: 35712226
The authors aim to develop siRNA therapeutics for cancer that can be administered systemically to target tumors and retard their growth. The efficacy of systemic delivery of siRNA to tumors...
9.
Lee D, Cardinale D, Nigro E, Butler C, Rutman A, Fassad M, et al.
Eur Respir J
. 2021 Apr;
58(4).
PMID: 33795320
Background: Development of therapeutic approaches for rare respiratory diseases is hampered by the lack of systems that allow medium-to-high-throughput screening of fully differentiated respiratory epithelium from affected patients. This is...
10.
Song H, Hart S, Du Z
Int J Pharm
. 2020 Nov;
592:120033.
PMID: 33144189
In recent years, gene therapy has made tremendous progress in the development of disease treatment. Among them, siRNA offers specificity of gene silencing, ease of synthesis, and short development period,...